Why I’m a Long-Term Investor in GlaxoSmithKline plc (GSK)

Page 1 of 2

LONDON — Back in 2007, I made the first of several purchases that together built up a small stake in GlaxoSmithKline plc (LSE:GSK) (NYSE:GSK) . Then in my early fifties, it seemed a prudent addition to the income-generating portfolio of stocks that I hope will help to secure a comfortable retirement for me.

Nor do I plan on selling the stake. In fact, by the end of this year, I expect my holding in GlaxoSmithKline to be even larger.

In short, I’m a long-term investor in the company and see it as a core part of my retirement strategy.

So let’s briefly review why, and discuss the merits that I see in a holding of GlaxoSmithKline.

GlaxoSmithKline plc (ADR) (NYSE:GSK)

Income generation
Priced today at 1,456 pence, GlaxoSmithKline’s shares are on a forecast price-to-earnings ratio of 12, which is around the market’s average. But the forecast yield is decidedly higher — at 5.3%, it’s around 50% more than the market average.

Income growth
Over the last 10 years, GlaxoSmithKline has grown its dividend at a compound rate of 4.9% a year. Now, that’s not “shoot the lights out” territory, but it’s still a decent track record — and one that in more recent times has also been comfortably exceeded. Roll the clock forward and if that growth is maintained, then in a further 10 years’ time my income will be 60% higher than it is today.

Defensive qualities
Better still, that income looks set to be sustainable, thanks to GlaxoSmithKline’s strong showing in both health care and consumer products. Significantly, the company’s dividend held up during the credit crunch and ensuing recession on 2008, when many companies cut their payouts to investors.

Employing around 99,000 people and manufacturing almost 4 billion packs of medicines and health care products every year, the company is also a consumer business with a robust collection of strong brands: Ribena, Horlicks, Lucozade, Aquafresh, Sensodyne, Panadol, Tums, Zovirax – and, of course, the Macleans range of toothpaste, mouthwash, and toothbrushes.

Page 1 of 2

Dividend Stock Alert - Billionaire Robbins' Top Dividend Idea With 70% Upside Potential

Get Paid 3.5% Per Year While Waiting For The Stock Appreciate 70%

Larry Robbins' Glenview Capital Opportunity Fund returned 101.7% in 2013 and Robbins personally made $750 million. The same fund returned 25.3% in 2014. In this FREE REPORT we will share Robbins' top dividend idea that yields 3.5% and has been increasing its dividends for 39 consecutive years. Robbins thinks the stock has the potential to appreciate 70%.

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Click Here to Read Comments
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!